Profile data is unavailable for this security.
About the company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
- Revenue in USD (TTM)522.75m
- Net income in USD-558.99m
- Incorporated2011
- Employees1.28k
- LocationUltragenyx Pharmaceutical Inc60 Leveroni CtNOVATO 94949-5746United StatesUSA
- Phone+1 (415) 483-8800
- Fax+1 (415) 483-8810
- Websitehttps://www.ultragenyx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.17bn | 383.00 | 4.52 | 1.95 | 4.32 | 96.36 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| MoonLake Immunotherapeutics | 0.00 | -80.77m | 3.31bn | 50.00 | -- | 6.70 | -- | -- | -1.29 | -1.29 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -16.25 | -- | -18.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -427.49m | 3.49bn | 390.00 | -- | 2.64 | -- | -- | -2.76 | -2.76 | 0.00 | 9.17 | 0.00 | -- | -- | 0.00 | -31.77 | -14.98 | -33.76 | -17.71 | -- | -- | -- | -104.50 | -- | -- | 0.0043 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Immunitybio Inc | 7.33m | -587.79m | 3.51bn | 672.00 | -- | -- | -- | 478.32 | -0.867 | -0.867 | 0.0108 | -1.07 | 0.0184 | -- | 1.53 | 11,675.16 | -147.53 | -112.76 | -182.67 | -316.07 | -- | -- | -8,018.00 | -37,700.74 | 2.64 | -2.19 | 4.22 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Rhythm Pharmaceuticals Inc | 112.53m | -261.57m | 3.63bn | 226.00 | -- | 323.37 | -- | 32.24 | -4.31 | -4.31 | 1.86 | 2.49 | 0.3136 | 1.18 | 6.65 | 497,920.30 | -72.15 | -47.21 | -90.85 | -52.84 | 88.61 | -- | -230.11 | -681.38 | 3.34 | -- | 0.417 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Alvotech SA | 393.92m | -441.45m | 3.75bn | 999.00 | -- | -- | -- | 9.52 | -1.90 | -1.90 | 1.56 | -1.29 | 0.3595 | 1.56 | 4.24 | 394,313.30 | -40.28 | -- | -47.87 | -- | 59.03 | -- | -112.07 | -- | 1.92 | -0.0519 | 1.41 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunovant Inc | 0.00 | -323.01m | 3.90bn | 207.00 | -- | 8.66 | -- | -- | -2.21 | -2.21 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -79.97 | -- | -92.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Ultragenyx Pharmaceutical Inc | 522.75m | -558.99m | 4.25bn | 1.28k | -- | 12.25 | -- | 8.13 | -6.46 | -6.46 | 6.02 | 3.76 | 0.3766 | 1.91 | 6.06 | 409,674.80 | -40.27 | -33.35 | -50.12 | -38.30 | 86.25 | 93.13 | -106.93 | -154.71 | 2.65 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Biohaven Ltd | 0.00 | -804.34m | 4.45bn | 239.00 | -- | 13.57 | -- | -- | -9.35 | -9.35 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -180.09 | -- | -236.99 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Alkermes Plc | 1.51bn | 502.58m | 4.48bn | 2.10k | 9.39 | 3.47 | 8.26 | 2.98 | 2.95 | 1.96 | 8.83 | 7.99 | 0.6788 | 1.32 | 4.24 | 716,724.30 | 22.67 | 1.34 | 28.90 | 1.74 | 83.17 | 83.32 | 33.39 | 2.12 | 3.03 | -- | 0.1827 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Arcellx Inc | 155.82m | -40.42m | 4.72bn | 130.00 | -- | 9.75 | -- | 30.27 | -0.7196 | -0.7196 | 2.98 | 8.95 | 0.226 | -- | -- | 1,198,600.00 | -5.86 | -38.82 | -7.56 | -45.41 | -- | -- | -25.94 | -339.38 | -- | -- | 0.022 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Crinetics Pharmaceuticals Inc | 1.04m | -277.91m | 5.09bn | 290.00 | -- | 5.53 | -- | 4,902.86 | -3.72 | -3.72 | 0.0139 | 10.30 | 0.0013 | -- | 0.1222 | 3,582.76 | -34.61 | -42.53 | -36.80 | -45.36 | -- | -- | -26,298.27 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Krystal Biotech Inc | 241.52m | 52.37m | 5.24bn | 229.00 | 103.14 | 5.92 | 88.24 | 21.71 | 1.77 | 1.77 | 8.21 | 30.80 | 0.2725 | 1.51 | 4.53 | 1,054,664.00 | 5.91 | -11.50 | 6.33 | -12.01 | 92.55 | -- | 21.68 | -492.85 | 7.76 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Ionis Pharmaceuticals Inc | 803.07m | -358.81m | 5.36bn | 927.00 | -- | 8.09 | -- | 6.67 | -2.45 | -2.45 | 5.50 | 4.20 | 0.267 | 0.3864 | 10.02 | 866,306.40 | -11.93 | -6.30 | -13.52 | -7.44 | 98.70 | 98.75 | -44.68 | -21.23 | 8.82 | -- | 0.6587 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| TG Therapeutics Inc | 264.79m | -14.36m | 5.38bn | 319.00 | -- | 28.01 | -- | 20.31 | -0.1067 | -0.1067 | 1.74 | 1.23 | 0.5775 | 0.5234 | 3.42 | 1,002,992.00 | -3.13 | -62.87 | -3.91 | -80.06 | 88.32 | -- | -5.42 | -405.03 | 3.91 | 0.2097 | 0.5596 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Ultragenyx Pharmaceutical Inc's reporting currency: US Dollar USD
42.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.81m | 10.64% |
| Sands Capital Management LLCas of 30 Sep 2024 | 5.12m | 5.55% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.63m | 5.02% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 4.01m | 4.35% |
| Alkeon Capital Management LLCas of 30 Sep 2024 | 3.01m | 3.27% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.97m | 3.22% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.66m | 2.89% |
| ClearBridge Investments LLCas of 30 Sep 2024 | 2.43m | 2.63% |
| Federated Global Investment Management Corp.as of 30 Sep 2024 | 2.11m | 2.29% |
| Rock Springs Capital Management LPas of 30 Sep 2024 | 1.98m | 2.15% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
